Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database
British Journal of Dermatology2016Vol. 175(2), pp. 296–301
Citations Over TimeTop 1% of 2016 papers
Johana Béné, Guillaume Moulis, Ismail Bennani, Marine Auffret, Pierrick Coupé, Samy Babai, Dominique Hillaire‐Buys, Joëlle Micallef, Sophie Gautier
Abstract
These data confirm a strong signal for an increased risk of bullous pemphigoid during DPP-IV inhibitor exposure. This adverse drug reaction is observed for each DPP-IV inhibitor, suggesting a class effect. The signal was higher with vildagliptin than with the other DPP-IV inhibitors.
Related Papers
- → No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan(2016)28 cited
- → Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study(2019)1 cited
- Dipeptidyl-peptidase IV inhibitors for treatment of type 2 diabetes mellitus:an overview of systematic reviews(2013)
- → Abstract 14879: Comparing the Risk of Heart Failure Among Different Dipeptidyl Peptidase 4 Inhibitors(2015)